CO5660265A2 - Metanosulfonato del ester etilico del acido 3-[(2-{[4-(hexiloxi-carbonilamino-imino-metil)-fenilamino]-metil}-1-metil-1h-benci-midazol-5-carbonil)-piridin-2-il-amino]-propionico y su utilizacion como medicamento - Google Patents

Metanosulfonato del ester etilico del acido 3-[(2-{[4-(hexiloxi-carbonilamino-imino-metil)-fenilamino]-metil}-1-metil-1h-benci-midazol-5-carbonil)-piridin-2-il-amino]-propionico y su utilizacion como medicamento

Info

Publication number
CO5660265A2
CO5660265A2 CO06019918A CO06019918A CO5660265A2 CO 5660265 A2 CO5660265 A2 CO 5660265A2 CO 06019918 A CO06019918 A CO 06019918A CO 06019918 A CO06019918 A CO 06019918A CO 5660265 A2 CO5660265 A2 CO 5660265A2
Authority
CO
Colombia
Prior art keywords
methyl
imino
amino
propionic
ethyl ester
Prior art date
Application number
CO06019918A
Other languages
English (en)
Inventor
Rainer Sobotta
Peter Sieger
Rolf Schmid
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34202202&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5660265(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CO5660265A2 publication Critical patent/CO5660265A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

1.- Metanosulfonato del éster etílico del ácido 3-[(2- {[4-(hexiloxicarbonilamino-imino-metil)-fenilamino ]-metil}-1-metil--1H-bencimidazol-5-carbonil)-piridin-2-il-amino]-propiónico en forma cristalina, caracterizado por un punto de fusión de Tp.f. = 180 + 3°C (forma I), (determinado por DSC; evaluación por pico máximo; tasa de calentamiento: 10°C/min). 2.- Metanosulfonato del éster etílico del ácido 3-[(2- {[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}-1-metil--1H-bencimidazol-5-carbonil)-piridin-2-il-amino]-propiónico en forma cristalina, caracterizado por un punto de fusión de Tp.f. = 190 + 3°C (forma II), (determinado por DSC; eva- Iuación por pico máximo; tasa de calentamiento: 10°C/min).3.- Metanosulfonato del éster etílico del ácido 3-[(2- {[4-(hexiloxicarbonilamino-imino-metil)-fenilamino ]-metil}-1-metil--1H-bencimidazol-5-carbonil)-piridin-2-il-amino]-propiónico en forma cristalina, caracterizado por un punto de fusión de T.p.f. = 120 + 5°C (semihidrato), (determinado por DSC; evaluación por pico máximo; tasa de calentamiento: 10°C/min).4.- Medicamento que contiene la sal metanosulfonato del éster etílico del ácido 3-[(2-{[4-(hexiloxicarbonilamino-imino- -metil)-fenilamino ]-metil}-1-metil-1H-bencimidazol-5-carbonil)- -piridin-2-il-amino]-propiónico conforme a una de las reivindicaciones 1 a 3, eventualmente junto a una o varias sustancias de soporte y/o diluyentes inertes.5.- Utilización del metanosulfonato del éster etílico del ácido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]--metil}-1-metil-1H-bencimidazol-5-carbonil)-piridin-2-il-amino]propiónico conforme a una de las reivindicaciones 1 a 3 para la preparación de un medicamento, el cual es adecuado para la profilaxis posoperativa de trombosis venosas profundas y para la profilaxis de ataques de apoplejía.
CO06019918A 2003-08-29 2006-02-28 Metanosulfonato del ester etilico del acido 3-[(2-{[4-(hexiloxi-carbonilamino-imino-metil)-fenilamino]-metil}-1-metil-1h-benci-midazol-5-carbonil)-piridin-2-il-amino]-propionico y su utilizacion como medicamento CO5660265A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10339862A DE10339862A1 (de) 2003-08-29 2003-08-29 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
CO5660265A2 true CO5660265A2 (es) 2006-07-31

Family

ID=34202202

Family Applications (1)

Application Number Title Priority Date Filing Date
CO06019918A CO5660265A2 (es) 2003-08-29 2006-02-28 Metanosulfonato del ester etilico del acido 3-[(2-{[4-(hexiloxi-carbonilamino-imino-metil)-fenilamino]-metil}-1-metil-1h-benci-midazol-5-carbonil)-piridin-2-il-amino]-propionico y su utilizacion como medicamento

Country Status (36)

Country Link
US (2) US20050234104A1 (es)
EP (2) EP1660482B1 (es)
JP (2) JP5348842B2 (es)
KR (1) KR101331039B1 (es)
CN (2) CN1845917B (es)
AR (2) AR045520A1 (es)
AT (2) ATE529420T1 (es)
AU (2) AU2004274139B2 (es)
BR (1) BRPI0413849A (es)
CA (2) CA2537054C (es)
CO (1) CO5660265A2 (es)
CY (2) CY1109299T1 (es)
DE (2) DE10339862A1 (es)
DK (2) DK2060569T3 (es)
EA (1) EA009736B1 (es)
EC (2) ECSP066399A (es)
ES (2) ES2326654T3 (es)
HK (2) HK1157760A1 (es)
HR (2) HRP20090311T1 (es)
IL (1) IL173885A (es)
ME (1) ME00340B (es)
MX (1) MXPA06001959A (es)
MY (2) MY145632A (es)
NO (2) NO334115B1 (es)
NZ (2) NZ578586A (es)
PE (1) PE20050348A1 (es)
PL (2) PL2060569T3 (es)
PT (2) PT1660482E (es)
RS (2) RS20060136A (es)
SG (1) SG145734A1 (es)
SI (2) SI1660482T1 (es)
TW (2) TWI418553B (es)
UA (1) UA85686C2 (es)
UY (2) UY28493A1 (es)
WO (1) WO2005028468A1 (es)
ZA (1) ZA200600518B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
US20050070537A1 (en) 2002-10-10 2005-03-31 Chris Rundfeldt Use of dihydroimidazolones for the treatment of dogs
DE10337697A1 (de) * 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
DE102005020002A1 (de) * 2005-04-27 2006-11-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Physiologisch verträgliche Salze von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester
DE102005025728A1 (de) * 2005-06-04 2006-12-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-Propionsäure-ethylester
DE102006054005A1 (de) * 2006-11-16 2008-05-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester
EP2288335A1 (en) * 2008-03-28 2011-03-02 Boehringer Ingelheim International GmbH Process for preparing orally administered dabigatran formulations
TWI436994B (zh) * 2008-07-14 2014-05-11 Boehringer Ingelheim Int 製備含有達比加群（ｄａｂｉｇａｔｒａｎ）之藥物組合物的新穎方法
US20110190352A1 (en) * 2008-08-19 2011-08-04 Boehringer Ingelheim International Gmbh Use of dabigatranetexilate for treating patients with pulmonary hypertension
NZ592616A (en) 2008-11-11 2013-04-26 Boehringer Ingelheim Int Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy
EP2429520A1 (en) 2009-05-14 2012-03-21 Boehringer Ingelheim International GmbH New combination therapy in treatment of oncological and fibrotic diseases
HUP1000069A2 (en) 2010-02-02 2012-05-02 Egis Gyogyszergyar Nyilvanosan M Kod Ruszvunytarsasag New salts for the preparation of pharmaceutical composition
EP2542224B1 (en) * 2010-03-01 2014-08-13 Ratiopharm GmbH Dabigatran etexilate-containing oral pharmaceutical composition
CA2792273A1 (en) 2010-03-08 2011-09-15 Ratiopharm Gmbh Dabigatran etexilate-containing pharmaceutical composition
ES2631980T3 (es) 2010-07-01 2017-09-07 Krka, Tovarna Zdravil, D.D., Novo Mesto Formas de dosificación orales farmacéuticas que comprenden dabigatrán etexilato y sus sales farmacéuticamente aceptables
WO2012027543A1 (en) 2010-08-25 2012-03-01 Teva Pharmaceuticals Usa, Inc. Solid state forms of dabigatran etexilate, dabigatran etexilate mesylate and processes for preparation thereof
ES2550771T3 (es) 2010-09-27 2015-11-12 Ratiopharm Gmbh Sal de bismesilato etexilato de dabigatrán, formas en estado sólido y proceso para la preparación de las mismas
WO2012077136A2 (en) * 2010-12-06 2012-06-14 Msn Laboratories Limited Process for the preparation of benzimidazole derivatives and its salts
HUP1100244A2 (hu) 2011-05-11 2012-11-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Gyógyszeripari intermedierek és eljárás elõállításukra
US20120301541A1 (en) 2011-05-24 2012-11-29 Haronsky Elina Compressed core for pharmaceutical composition
JP2015500853A (ja) 2011-12-22 2015-01-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 即時放出マルチユニットペレットシステム
US9212166B2 (en) 2012-01-20 2015-12-15 Cadila Healthcare Limited Process for the preparation of dabigatran etexilate mesylate and polymorphs of intermediates thereof
WO2013110567A1 (en) 2012-01-24 2013-08-01 Boehringer Ingelheim International Gmbh Novel orally administered dabigatran formulation
JP6215239B2 (ja) 2012-02-21 2017-10-18 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ ダビガトランエテキシラートの経口医薬組成物
EP2631234A1 (en) 2012-02-23 2013-08-28 Esteve Química, S.A. Solid forms of dabigatran etexilate mesylate and processes for their preparation
WO2013144971A1 (en) 2012-03-27 2013-10-03 Cadila Healthcare Limited New solid forms of dabigatran etexilate bisulfate and mesylate and processes to prepare them
EP2834224B1 (en) 2012-04-02 2018-06-06 MSN Laboratories Limited Process for the preparation of benzimidazole derivatives and salts thereof
JP2015522596A (ja) * 2012-07-16 2015-08-06 インテルキム、ソシエダッド アノニマ ダビガトランエテキシラートの合成のための中間体を調製する方法及び該中間体の結晶形
EP2890692A1 (en) 2012-08-31 2015-07-08 Ranbaxy Laboratories Limited Process for the preparation of crystalline form i of methanesulfonate salt of dabigatran etexilate
CN103664882A (zh) * 2012-09-20 2014-03-26 天津药物研究院 结晶变体形态的达比加群酯及其制备方法和用途
CN103864756B (zh) * 2012-12-11 2018-06-15 四川海思科制药有限公司 丁二磺酸达比加群酯及其制备方法和用途
EP2835370A1 (en) 2013-08-08 2015-02-11 Medichem, S.A. New crystals of dabigatran etexilate mesylate
CN104418840A (zh) * 2013-09-05 2015-03-18 天津汉瑞药业有限公司 甲磺酸达比加群酯无水化合物
WO2015128875A2 (en) 2014-02-26 2015-09-03 Megafine Pharma (P) Ltd. A process for preparation of dabigatran etexilate mesylate and intermediates thereof
CN104892574A (zh) 2014-03-04 2015-09-09 浙江海正药业股份有限公司 达比加群酯甲磺酸盐的晶型及其制备方法和用途
US9820988B2 (en) 2014-03-24 2017-11-21 Boehringer Ingelheim Vetmedica Gmbh Treatment of epileptic disorders in feline animals
CN104974137A (zh) * 2014-04-04 2015-10-14 江苏天士力帝益药业有限公司 达比加群酯甲磺酸盐新晶型及其制备方法
CN105461686A (zh) * 2014-08-25 2016-04-06 江苏豪森药业股份有限公司 制备高纯度甲磺酸达比加群酯晶型的方法
CN104825422B (zh) * 2014-09-29 2017-12-12 普济生物科技（台州）有限公司 含达比加群酯甲磺酸盐的药物组合物及其制备方法
EP3251672B1 (en) 2014-12-31 2023-02-01 Shenzhen Pharmacin Co., Ltd. Pharmaceutical composition comprising dabigatran etexilate and preparation method therefor
CN104725360A (zh) * 2015-04-09 2015-06-24 重庆东得医药科技有限公司 一种甲磺酸达比加群酯ⅰ晶型的制备方法
WO2017111637A1 (en) 2015-12-23 2017-06-29 Zaklady Farmaceutyczne Polpharma Sa Pharmaceutical composition comprising dabigatran or a pharmaceutically acceptable salt thereof
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
CN107778291A (zh) * 2016-08-31 2018-03-09 亚宝药业集团股份有限公司 一种甲磺酸达比加群酯晶型ⅱ的制备方法
CN116813691B (zh) 2018-10-29 2024-04-12 丽珠医药集团股份有限公司 新的二肽类化合物及其用途
JP2020193184A (ja) * 2019-05-30 2020-12-03 ダイト株式会社 ダビガトランエテキシラートメタンスルホン酸塩の形態ｉの製造方法
EP3771465A1 (en) 2019-08-01 2021-02-03 Zaklady Farmaceutyczne Polpharma SA Pharmaceutical composition comprising dabigatran etexilate
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
CN114380793B (zh) * 2020-10-20 2024-02-23 北京澳合药物研究院有限公司 一种甲磺酸达比加群酯晶型i的制备方法及其应用
US11446286B1 (en) * 2022-02-28 2022-09-20 King Faisal University Treatment of fungal infections using dabigatran etexilate

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) * 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
US4427468A (en) * 1976-01-16 1984-01-24 Her Majesty The Queen In Right Of Canada Curable propellant binding systems with bonding agent combination
DE3000979A1 (de) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
DE3124090A1 (de) * 1981-06-19 1983-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale dipyridamolformen
DE3126703A1 (de) * 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
JPS58134033A (ja) 1982-02-02 1983-08-10 Fujisawa Pharmaceut Co Ltd 医薬組成物
US4675405A (en) * 1984-09-21 1987-06-23 American Home Products Corporation Quinoline compounds as antiallergic and antithrombotic agents
DE4129603A1 (de) * 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5416099A (en) * 1991-10-29 1995-05-16 Merck & Co., Inc. Fibrinogen receptor antagonists
ZA928276B (en) 1991-10-31 1993-05-06 Daiichi Seiyaku Co Aromatic amidine derivates and salts thereof.
JPH07509702A (ja) * 1992-08-05 1995-10-26 エフ・エイチ・フォールディング・アンド・カンパニー・リミテッド ペレット薬剤組成物
JPH06340619A (ja) 1993-05-03 1994-12-13 Bristol Myers Squibb Co グアニジニルまたはアミジニル置換メチルアミノ複素環トロンビン抑制剤
CA2134192A1 (en) 1993-11-12 1995-05-13 Michael L. Denney 5, 6-bicyclic glycoprotein iib/iiia antagonists
PE121699A1 (es) * 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
US6414008B1 (en) * 1997-04-29 2002-07-02 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions
DE19752843C2 (de) 1997-11-28 2003-01-09 Byk Gulden Lomberg Chem Fab Arzneimittelzubereitung in Tabletten- oder Pelletform für Pantoprazol und Omeprazol
DE10133786A1 (de) 2001-07-16 2003-02-06 Boehringer Ingelheim Pharma Verwendung von Thrombin-Inhibitoren zur Behandlung von Arthritis
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
CA2476054C (en) * 2002-03-07 2011-11-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical composition for the oral administration of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino)-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino)-propionic acid ethyl ester and the salts thereof
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
DE10245624A1 (de) * 2002-09-30 2004-04-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Oral zu applizierende Darreichungsform für 3-[(2-{[4-(Hexyloxycarbonylaminoimino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2yl-amino]-propinsäure-ethylester und dessen Salze
DE10209982A1 (de) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe
DE10235639A1 (de) * 2002-08-02 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Prodrugs von 1-Methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carbonsäure-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amid, ihre Herstellung und ihre Verwendung als Arzneimittel
MXPA05011432A (es) * 2003-04-24 2006-03-21 Boehringer Ingelheim Int Uso de dipiridamol o mopidamol para tratamiento y prevencion de enfermedades trombo-embolicas y desordenes originados por formacion excesiva de trombina y/o por expresion elevada de receptores de trombina.
DE10337697A1 (de) * 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
US20050107438A1 (en) * 2003-09-03 2005-05-19 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising 3-[(2-{[4-(Hexyloxycarbonylaminoiminomethyl) phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester or a salt therefore
EP1609784A1 (de) * 2004-06-25 2005-12-28 Boehringer Ingelheim Pharma GmbH & Co.KG Verfahren zur Herstellung von 4-(Benzimidazolylmethylamino)-Benzamidinen
US20060222640A1 (en) * 2005-03-29 2006-10-05 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for treatment of thrombosis
DE102005020002A1 (de) * 2005-04-27 2006-11-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Physiologisch verträgliche Salze von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester
DE102005025728A1 (de) * 2005-06-04 2006-12-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-Propionsäure-ethylester
DE102005061624A1 (de) * 2005-12-21 2007-06-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verbessertes Verfahren zur Herstellung von Salzen von 4-(Benzimidazolylmethylamino)-Benzamidinen
DE102005061623A1 (de) * 2005-12-21 2007-06-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verbessertes Verfahren zur Herstellung von 4-(Benzimidazolylmethylamino)-Benzamidinen und deren Salzen

Also Published As

Publication number Publication date
HRP20090311T1 (en) 2009-07-31
TW200512206A (en) 2005-04-01
NZ545984A (en) 2009-08-28
CN102167695A (zh) 2011-08-31
KR101331039B1 (ko) 2013-11-20
JP2011178803A (ja) 2011-09-15
EP2060569B1 (de) 2011-10-19
KR20070031830A (ko) 2007-03-20
UY28493A1 (es) 2005-03-31
ATE529420T1 (de) 2011-11-15
AU2004274139A1 (en) 2005-03-31
NZ578586A (en) 2011-01-28
ZA200600518B (en) 2006-12-27
HRP20120028T1 (hr) 2012-01-31
HK1157760A1 (en) 2012-07-06
CA2537054A1 (en) 2005-03-31
ES2375896T3 (es) 2012-03-07
ES2326654T3 (es) 2009-10-16
NO20130778L (no) 2006-03-28
SI2060569T1 (sl) 2012-01-31
MXPA06001959A (es) 2006-05-17
UA85686C2 (ru) 2009-02-25
PT1660482E (pt) 2009-06-04
EP1660482B1 (de) 2009-04-29
UY32342A (es) 2011-07-29
CN1845917A (zh) 2006-10-11
US20050234104A1 (en) 2005-10-20
EA009736B1 (ru) 2008-02-28
ME00340B (me) 2011-05-10
PL2060569T3 (pl) 2012-03-30
US20080119523A1 (en) 2008-05-22
SG145734A1 (en) 2008-09-29
EA200600381A1 (ru) 2006-08-25
CN1845917B (zh) 2011-05-11
ECSP066399A (es) 2006-09-18
JP5566332B2 (ja) 2014-08-06
DE502004009431D1 (en) 2009-06-10
TWI375674B (en) 2012-11-01
JP2007504106A (ja) 2007-03-01
IL173885A (en) 2015-04-30
CY1109299T1 (el) 2014-07-02
TW201202217A (en) 2012-01-16
AR045520A1 (es) 2005-11-02
CA2537054C (en) 2011-12-06
MY145696A (en) 2012-03-30
ATE430145T1 (de) 2009-05-15
TWI418553B (zh) 2013-12-11
BRPI0413849A (pt) 2006-10-24
EP1660482A1 (de) 2006-05-31
MEP50608A (en) 2011-02-10
AU2010201457B2 (en) 2012-05-10
AU2010201457A1 (en) 2010-05-06
DE10339862A1 (de) 2005-03-24
PE20050348A1 (es) 2005-06-15
PT2060569E (pt) 2011-12-29
CA2749579C (en) 2013-04-16
MY145632A (en) 2012-03-15
CN102167695B (zh) 2013-06-19
RS53370B (en) 2014-10-31
DK1660482T3 (da) 2009-08-24
AR073225A2 (es) 2010-10-20
PL1660482T3 (pl) 2009-08-31
ECSP11006399A (es) 2011-12-30
DK2060569T3 (da) 2012-01-23
CA2749579A1 (en) 2005-03-31
AU2004274139B2 (en) 2010-05-13
JP5348842B2 (ja) 2013-11-20
CY1112222T1 (el) 2015-12-09
RS20060136A (en) 2008-06-05
HK1096682A1 (es) 2007-06-08
NO20061420L (no) 2006-03-28
US7932273B2 (en) 2011-04-26
WO2005028468A1 (de) 2005-03-31
NO334115B1 (no) 2013-12-16
EP2060569A1 (de) 2009-05-20
SI1660482T1 (sl) 2009-10-31
IL173885A0 (en) 2006-07-05

Similar Documents

Publication Publication Date Title
CO5660265A2 (es) Metanosulfonato del ester etilico del acido 3-[(2-{[4-(hexiloxi-carbonilamino-imino-metil)-fenilamino]-metil}-1-metil-1h-benci-midazol-5-carbonil)-piridin-2-il-amino]-propionico y su utilizacion como medicamento
PH12016501603A1 (en) 2-(het)aryl-substituted condensed bicyclic heterocycle derivatives as pest control agents
CY1116455T1 (el) Υποκατεστημενα 4-αρυλο-1,4-διυδρο-1,6-ναφθυριδιν αμιδια και η χρηση τους
MY148258A (en) Phenylamino-benzoxazole substituted carboxylic acids, method for their production and use thereof as medicaments
MY148096A (en) 4,5-diphenyl-pyrimidinyl-amino substituted carboxylic acids, method for the production and use thereof as medicaments
MY148483A (en) 4,5-diphenyl-pyrimidinyl-oxy or-mercapto substituted carboxylic acids, method for the production and use thereof as medicaments
MX2007006311A (es) Acidos hidroxibifenilcarboxilicos y derivados, metodo para producirlos y su uso.
WO2012122340A8 (en) Soluble guanylate cyclase activators
CL2008002315A1 (es) Compuestos derivados de acido piridin, pirimidin y quinolin aminonbenzoico; composicion y combinacion farmaceuticas; y uso para el tratamiento de una enfermedad susceptible de aliviarse mediante la inhibicion de deshidroorotato deshidrogenasa tales como artritis reumatoide, espondilitis anquilosante, esclerosis multiple, psoriasis, entre otras.
WO2008155069A3 (de) Substituierte oxazolidinone und ihre verwendung
MX348131B (es) Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos.
CL2012003121A1 (es) Método para producir un elemento de filtro que comprende un aditivo sólido a temperatura ambiente, calentar y fundir el aditivo y conformar el material de filtro laminado y el aditivo en un elemento de filtro; elemento de filtro; filtro; y artículo para fumar.
UY30337A1 (es) Acidos carboxilicos sustituidos con 4,5-difenilpirimidinilo, procedimientos para su preparacion y su uso como productos farmacéuticos.
CL2011000955A1 (es) Compuestos derivados de 2-piridina fusionado a un anillo piridina; composicion herbicida que contiene a dichos compuestos; y metodo para combatir el crecimiento de plantas indeseadas.
WO2010149578A3 (en) Novel biphenyl and phenyl-pyridine amides
CO6531458A2 (es) Nuevos compuestos de espiropiperidina
NZ589764A (en) NMDA receptor antagonists for the treatment of neuropsychiatric disorders
WO2015142903A3 (en) Method of controlling lactate production with piperdine-dione derivatives
ECSP12011930A (es) Nuevos compuestos de espiropiperidina
MX339033B (es) Derivados de acido antranilico.
CL2013000785A1 (es) Compuestos 3-fluoro-4-(5-fluoro-6-(4-(3-(2-fluoropropan-2-il)-1,2,4-oxadiazol-5-il)piperidin-1-il)pirimidin-4-ilamino)(-n,n-dimetilbenzamida o –n-metilbenzamida o –benzamida); composicion farmaceutica; metodo de preparacion; producto farmaceutico; metodo de tratamiento; uso para tratar un trastorno neurologico, entre otros.
NZ733574A (en) Dihydroindolizinone derivative
UA88481C2 (ru) Донепезила фумарат, пригодный для получения фармацевтических композиций
DE602006001699D1 (de) Stabile pharmazeutische Zusammensetzung mit Linezolid Form IV
CY1117416T1 (el) Παραγωγα βενζαζολης ως προσδετες του υποδοχεα ισταμινης η4

Legal Events

Date Code Title Description
FC Application refused